Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience
Abstract Background Systemic juvenile idiopathic arthritis (sJIA) is a severe form of juvenile arthritis that is characterized by chronic joint inflammation and systemic symptoms such as fever, rash, and organ involvement. Anti-IL-6 receptor monoclonal antibody tocilizumab is an effective treatment....
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-03-01
|
| Series: | Pediatric Rheumatology Online Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12969-024-00974-4 |
| _version_ | 1797247377985241088 |
|---|---|
| author | Lingzhi Qiu Le Ma Yifan Xie Jing Jin Yuting Pan Shumin Li Zhidan Fan Haiguo Yu |
| author_facet | Lingzhi Qiu Le Ma Yifan Xie Jing Jin Yuting Pan Shumin Li Zhidan Fan Haiguo Yu |
| author_sort | Lingzhi Qiu |
| collection | DOAJ |
| description | Abstract Background Systemic juvenile idiopathic arthritis (sJIA) is a severe form of juvenile arthritis that is characterized by chronic joint inflammation and systemic symptoms such as fever, rash, and organ involvement. Anti-IL-6 receptor monoclonal antibody tocilizumab is an effective treatment. However, some patients still experience persisting or recurrent symptoms and the real-world effectiveness of canakinumab in Chinese patients with sJIA has never been reported. Therefore, this study aimed to assess the efficacy and safety of canakinumab in Chinese patients with sJIA using real-world data. Methods We conducted a retrospective study on children with active sJIA. Clinical features, laboratory data, corticosteroid dosage, and adverse events (AEs) were collected at baseline and at 4, 8, 12, and 24 weeks after initiating canakinumab treatment. Results Seven female and four male patients were included in the study. All patients had previously been treated with tocilizumab and were administered canakinumab for 12.4 ± 3.4 months. Notably, significant improvements were observed in both clinical signs and symptoms as well as laboratory indicators. Four children under corticosteroid treatment were able to successfully discontinue their corticosteroid therapy: one at week 4, two at week 12, and one at week 24. Notably, there was a significant reduction in the number of tender and swollen joints (P = 0.0059) as well as the systemic juvenile arthritis disease activity score (P < 0.0001). The most common AE was infection, but no patients experienced serious AEs. No cases of macrophage activation syndrome or death were reported during the follow-up period. Conclusions Canakinumab was found to be potentially efficacious and safe in Chinese patients with sJIA. No new AEs were observed with canakinumab treatment. |
| first_indexed | 2024-04-24T19:57:44Z |
| format | Article |
| id | doaj.art-0a6df06d6f834ca192af351ee0176a79 |
| institution | Directory Open Access Journal |
| issn | 1546-0096 |
| language | English |
| last_indexed | 2024-04-24T19:57:44Z |
| publishDate | 2024-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Pediatric Rheumatology Online Journal |
| spelling | doaj.art-0a6df06d6f834ca192af351ee0176a792024-03-24T12:13:11ZengBMCPediatric Rheumatology Online Journal1546-00962024-03-0122111010.1186/s12969-024-00974-4Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experienceLingzhi Qiu0Le Ma1Yifan Xie2Jing Jin3Yuting Pan4Shumin Li5Zhidan Fan6Haiguo Yu7Department of Rheumatology and Immunology, Children’s Hospital of Nanjing Medical UniversityDepartment of Rheumatology and Immunology, Children’s Hospital of Nanjing Medical UniversityDepartment of Rheumatology and Immunology, Children’s Hospital of Nanjing Medical UniversityDepartment of Rheumatology and Immunology, Children’s Hospital of Nanjing Medical UniversityDepartment of Rheumatology and Immunology, Children’s Hospital of Nanjing Medical UniversityDepartment of Rheumatology and Immunology, Children’s Hospital of Nanjing Medical UniversityDepartment of Rheumatology and Immunology, Children’s Hospital of Nanjing Medical UniversityDepartment of Rheumatology and Immunology, Children’s Hospital of Nanjing Medical UniversityAbstract Background Systemic juvenile idiopathic arthritis (sJIA) is a severe form of juvenile arthritis that is characterized by chronic joint inflammation and systemic symptoms such as fever, rash, and organ involvement. Anti-IL-6 receptor monoclonal antibody tocilizumab is an effective treatment. However, some patients still experience persisting or recurrent symptoms and the real-world effectiveness of canakinumab in Chinese patients with sJIA has never been reported. Therefore, this study aimed to assess the efficacy and safety of canakinumab in Chinese patients with sJIA using real-world data. Methods We conducted a retrospective study on children with active sJIA. Clinical features, laboratory data, corticosteroid dosage, and adverse events (AEs) were collected at baseline and at 4, 8, 12, and 24 weeks after initiating canakinumab treatment. Results Seven female and four male patients were included in the study. All patients had previously been treated with tocilizumab and were administered canakinumab for 12.4 ± 3.4 months. Notably, significant improvements were observed in both clinical signs and symptoms as well as laboratory indicators. Four children under corticosteroid treatment were able to successfully discontinue their corticosteroid therapy: one at week 4, two at week 12, and one at week 24. Notably, there was a significant reduction in the number of tender and swollen joints (P = 0.0059) as well as the systemic juvenile arthritis disease activity score (P < 0.0001). The most common AE was infection, but no patients experienced serious AEs. No cases of macrophage activation syndrome or death were reported during the follow-up period. Conclusions Canakinumab was found to be potentially efficacious and safe in Chinese patients with sJIA. No new AEs were observed with canakinumab treatment.https://doi.org/10.1186/s12969-024-00974-4CanakinumabInterleukin-1Systemic juvenile idiopathic arthritis |
| spellingShingle | Lingzhi Qiu Le Ma Yifan Xie Jing Jin Yuting Pan Shumin Li Zhidan Fan Haiguo Yu Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience Pediatric Rheumatology Online Journal Canakinumab Interleukin-1 Systemic juvenile idiopathic arthritis |
| title | Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience |
| title_full | Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience |
| title_fullStr | Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience |
| title_full_unstemmed | Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience |
| title_short | Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience |
| title_sort | efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis the first chinese experience |
| topic | Canakinumab Interleukin-1 Systemic juvenile idiopathic arthritis |
| url | https://doi.org/10.1186/s12969-024-00974-4 |
| work_keys_str_mv | AT lingzhiqiu efficacyandsafetyofcanakinumabinsystemicjuvenileidiopathicarthritisthefirstchineseexperience AT lema efficacyandsafetyofcanakinumabinsystemicjuvenileidiopathicarthritisthefirstchineseexperience AT yifanxie efficacyandsafetyofcanakinumabinsystemicjuvenileidiopathicarthritisthefirstchineseexperience AT jingjin efficacyandsafetyofcanakinumabinsystemicjuvenileidiopathicarthritisthefirstchineseexperience AT yutingpan efficacyandsafetyofcanakinumabinsystemicjuvenileidiopathicarthritisthefirstchineseexperience AT shuminli efficacyandsafetyofcanakinumabinsystemicjuvenileidiopathicarthritisthefirstchineseexperience AT zhidanfan efficacyandsafetyofcanakinumabinsystemicjuvenileidiopathicarthritisthefirstchineseexperience AT haiguoyu efficacyandsafetyofcanakinumabinsystemicjuvenileidiopathicarthritisthefirstchineseexperience |